STUDY OBJECTIVES: Different therapeutic strategies have been investigated for the treatment of positional obstructive sleep apnea, but more evidence is needed about efficacy and compliance. The objective of this study was to describe the efficacy of vibrotactile neck-based treatment in patients with positional obstructive sleep apnea with different degrees of obstructive sleep apnea severity who were followed for 6 months. METHODS: This is a retrospective study including 162 patients with positional obstructive sleep apnea undergoing vibrotactile neck-based positional therapy. We compared polysomnographic data obtained at baseline and during positional therapy after 1 month. We performed a subgroup analysis based on obstructive sleep apnea severity. Furthermore, we analyzed follow-up data in 84/162 (51.8%) patients with particular focus on discontinuation and complications related to the device. RESULTS: We observed a significant difference between mean baseline obstructive apnea-hypopnea index (OAHI; 21.9 ± 9.9 events/h) and during positional therapy (12 ± 9.2 events/h; P < .01). Moreover, 87/162 (54.9%) patients showed a reduced baseline OAHI of at least 50% and 38/162 (23.4%) achieved complete disease control (OAHI < 5 events/h). At subgroup analysis, at least 50% reduction from baseline OAHI was observed in 56.8% of patients with mild, 55% with moderate, and 47.4% with severe OAHI, whereas complete control of disease was achieved in 50% of patients with mild, 22.5% with moderate, and 7.9% with severe OAHI. At a 6-month follow-up, only 35/84 patients (41.6%) were regularly using the device, with a mean of 5.9 ± 1.2 days per week. CONCLUSIONS: Our results on the efficacy and long-term adherence to vibrotactile neck-based positional therapy showed that positional therapy can be an efficient first-line treatment option for mild positional obstructive sleep apnea and in selected cases of moderate disease. Long-term compliance is limited because of complications and low satisfaction in some patients.
STUDY OBJECTIVES: Different therapeutic strategies have been investigated for the treatment of positional obstructive sleep apnea, but more evidence is needed about efficacy and compliance. The objective of this study was to describe the efficacy of vibrotactile neck-based treatment in patients with positional obstructive sleep apnea with different degrees of obstructive sleep apnea severity who were followed for 6 months. METHODS: This is a retrospective study including 162 patients with positional obstructive sleep apnea undergoing vibrotactile neck-based positional therapy. We compared polysomnographic data obtained at baseline and during positional therapy after 1 month. We performed a subgroup analysis based on obstructive sleep apnea severity. Furthermore, we analyzed follow-up data in 84/162 (51.8%) patients with particular focus on discontinuation and complications related to the device. RESULTS: We observed a significant difference between mean baseline obstructive apnea-hypopnea index (OAHI; 21.9 ± 9.9 events/h) and during positional therapy (12 ± 9.2 events/h; P < .01). Moreover, 87/162 (54.9%) patients showed a reduced baseline OAHI of at least 50% and 38/162 (23.4%) achieved complete disease control (OAHI < 5 events/h). At subgroup analysis, at least 50% reduction from baseline OAHI was observed in 56.8% of patients with mild, 55% with moderate, and 47.4% with severe OAHI, whereas complete control of disease was achieved in 50% of patients with mild, 22.5% with moderate, and 7.9% with severe OAHI. At a 6-month follow-up, only 35/84 patients (41.6%) were regularly using the device, with a mean of 5.9 ± 1.2 days per week. CONCLUSIONS: Our results on the efficacy and long-term adherence to vibrotactile neck-based positional therapy showed that positional therapy can be an efficient first-line treatment option for mild positional obstructive sleep apnea and in selected cases of moderate disease. Long-term compliance is limited because of complications and low satisfaction in some patients.
Authors: Wietske Richard; Dennis Kox; Cindy den Herder; Martin Laman; Harm van Tinteren; Nico de Vries Journal: Eur Arch Otorhinolaryngol Date: 2006-06-27 Impact factor: 2.503
Authors: W J Randerath; J Verbraecken; S Andreas; G Bettega; A Boudewyns; E Hamans; F Jalbert; J R Paoli; B Sanner; I Smith; B A Stuck; L Lacassagne; M Marklund; J T Maurer; J L Pepin; A Valipour; T Verse; I Fietze Journal: Eur Respir J Date: 2011-03-15 Impact factor: 16.671
Authors: M Jeffery Mador; Thomas J Kufel; Ulysses J Magalang; S K Rajesh; Veena Watwe; Brydon J B Grant Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: E Scarano; G Della Marca; E De Corso; S Dittoni; W Di Nardo; D Meucci; G Bastanza; R Gallus; A Losurdo; E Testani; G Paludetti Journal: Acta Otorhinolaryngol Ital Date: 2014-10 Impact factor: 2.124
Authors: Marijke Dieltjens; Anneclaire V Vroegop; Annelies E Verbruggen; Kristien Wouters; Marc Willemen; Wilfried A De Backer; Johan A Verbraecken; Paul H Van de Heyning; Marc J Braem; Nico de Vries; Olivier M Vanderveken Journal: Sleep Breath Date: 2014-10-22 Impact factor: 2.816
Authors: Francesco Gambino; Marta Maria Zammuto; Alessandro Virzì; Giosafat Conti; Maria Rosaria Bonsignore Journal: Intern Emerg Med Date: 2022-04-23 Impact factor: 5.472